Gene Therapy Market Analysis Report On The Basis Of Indication, Vector Type, Region And Forecast 2027

17/apr/2020 12:00:40 Grand View Research Contatta l'autore

Questo comunicato è stato pubblicato più di 3 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Gene Therapy Market

San Francisco, 17 April 2020: The Report Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type, By Region, And Segment Forecasts, 2020 - 2027

The global gene therapy market size is expected to reach USD 6.6 billion by 2027, at a CAGR of 16.6% over the forecast period, according to a new report by Grand View Research, Inc. The approval of early CAR-T-based gene therapy products has created lucrative avenues in product approvals over expanded indications. Clinical trials for T-cell therapies each year has risen exponentially in the recent past. Constant developments in CAR-T cell therapy are recognized as one of the key driving factors for market growth.

Although gene therapy has primarily been used for cancer treatment, it increasingly finds application in the treatment of various rare and incurable diseases. Approval of products for non-cancer applications, such as approval of Bluebird Bio’s Zynteglo in June 2019 for β-thalassemia, indicates the shift in preferences of companies toward other untapped segments.

Gene therapies involve complex molecules and hence manufacturing these molecules is a challenge for developers, particularly in with regard to specialized manufacturing facilities and highly skilled technical personnel. This has created lucrative avenues for contract service providers operating in the space.

Access Research Report of Gene Therapy Market https://www.grandviewresearch.com/industry-analysis/gene-therapy-market

Further key findings from the study suggest:

  • Since viral vectors are the most conventional method for the delivery of genes, several operating players have designed their gene therapy programs based on viral vectors
  • In 2019, the lentivirus and retrovirus generated significant revenue owing to the approval of lentivirus-based Kymriah and retrovirus-based Yescarta in 2017 by the U.S. FDA
  • Among various indications, a majority of the revenue share is generated by various forms of cancer. This is attributed to the presence of approved products for cancer forms such as acute lymphoblastic leukemia (ALL), large B-cell lymphoma, and melanoma
  • North America dominated the global gene therapy market in 2019 as U.S. is the largest market for clinical trials related to gene therapy, since around 60.0% of all clinical trials in the world are carried out in the country. Moreover, FDA approval of Kymriah and Yescarta in U.S. in 2017 and Kymriah in Canada in 2018 has resulted in huge investments by sponsors and government agencies in North America
  • Key market players include Bluebird Bio, Novartis AG, UniQure NV, Gilead Sciences, Spark Therapeutics LLC, and Celgene Corporation
  • These players are engaged in signing licensing, commercialization, and development agreements with other market participants to expand their business operations in cell and gene therapy domain. For instance, Novartis Pharmaceuticals received commercialization rights for Spark Therapeutics’ Luxturna for selling the product outside U.S.

Browse more reports of this category by Grand View Research at: https://www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented the global gene therapy market on the basis of indication, vector type, and region:

Gene Therapy Indication Outlook (Revenue, USD Million, 2016 - 2027)

  • Acute Lymphoblastic Leukemia (ALL)
  • Inherited Retinal Disease
  • Large B-cell Lymphoma
  • ADA-SCID
  • Melanoma (Lesions)
  • Beta-Thalassemia Major/SCD
  • Head & Neck Squamous Cell Carcinoma
  • Peripheral Arterial Disease
  • Spinal Muscular Atrophy (SMA) 
  • Others

Gene Therapy Vector Type Outlook (Revenue, USD Million, 2016 - 2027)

  • Lentivirus
  • AAV
  • Retrovirus & Gammaretrovirus
  • Modified Herpes Simplex Virus
  • Adenovirus
  • Non-viral Plasmid Vector

Gene Therapy Regional Outlook (Revenue, USD Million, 2016 - 2027)

  • North America
  • Europe
  • Asia Pacific

Access Press Release of Gene Therapy Market @ https://www.grandviewresearch.com/press-release/global-gene-therapy-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information:www.grandviewresearch.com

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl